Julie Farrar

Dr. Julie Farrar

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Journal of Surgical Research
Verified
Journal Article
Closed access
JFJulie Farrar
Julie Farrar
MDMolly Elizabeth Droege
Molly Elizabeth Droege
CPCarolyn Dosen Philpott
Carolyn Dosen Philpott
EMEric William Mueller
Eric William Mueller
NENeil Edward Ernst
Neil Edward Ernst
CDChristopher Allen Droege
Christopher Allen Droege

18 October 2022 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
SLS. Casey Laizure
S. Casey Laizure
FCFeng Chen
Feng Chen
JFJulie Farrar
Julie Farrar
DADina Ali
Dina Ali
BYBing Yang
Bing Yang
RPRobert B. Parker
Robert B. Parker

19 November 2021 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
JFJulie Farrar
Julie Farrar
SMScott W. Mueller
Scott W. Mueller
VSVictoria Stevens
Victoria Stevens
TKTyree H. Kiser
Tyree H. Kiser
STSim Taleb
Sim Taleb
PRPaul Reynolds
Paul Reynolds
Background: Fraction unbound has been used as a surrogate for antimicrobial sieving coefficient (SC) to predict extracorporeal clearance in critically ill patients on continuous renal replacement therapy (CRRT), but this is based largely on expert opinion.Objectives: To examine relationships between package insert-derived fraction unbound (Fu-P), study-specific fraction unbound (Fu-S), and SC in critically ill patients receiving CRRT.Methods: English-language studies containing patient-specific in vivo pharmacokinetic parameters for antimicrobials in critically ill patients requiring CRRT were included. The primary outcome included correlations between Fu-S, Fu-P, and SC. Secondary outcomes included correlations across protein binding quartiles, serum albumin, and predicted in-hospital mortality, and identification of predictors for SC through multivariable analysis.Results: Eighty-nine studies including 32 antimicrobials were included for analysis. SC was moderately correlated to Fu-S (R2 = 0.55, P < 0.001) and Fu-P (R2 = 0.41, P < 0.001). SC was best correlated to Fu-S in first (92%) quartiles of fraction unbound and above median albumin concentrations of 24.5 g/L (R2 = 0.71, P = 0.07). Conversely, correlation was weaker in patients with mortality estimates greater than the median of 55% (R2 = 0.06, P = 0.84). SC and Fu-P were also best correlated in the first quartile of antimicrobial fraction unbound (R2 = 0.66, P < 0.001). Increasing Fu-P, flow rate, membrane surface area, and serum albumin, and decreasing physiologic charge significantly predicted increasing SC.Conclusions: Fu-S and Fu-P were both reasonably correlated to SC. Caution should be taken when using Fu-S to calculate extracorporeal clearance in antimicrobials with 69%–92% fraction unbound or with >55% estimated in-hospital patient mortality. Fu-P may serve as a rudimentary surrogate for SC when Fu-S is unavailable.

14 May 2020 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
JFJulie Farrar
Julie Farrar
KGKatelyn M. Garner
Katelyn M. Garner
JSJoseph M. Swanson
Joseph M. Swanson
LMLouis J. Magnotti
Louis J. Magnotti
MCMartin A. Croce
Martin A. Croce
GWG. Christopher Wood
G. Christopher Wood
What is known and objective Stenotrophomonas maltophilia is an intrinsically multidrug‐resistant (MDR) organism which commonly presents as a respiratory tract infection. S. maltophilia is typically treated with high‐dose sulfamethoxazole/trimethoprim (SMX/TMP). However, SMX/TMP and other treatment options for S. maltophilia can be limited because of resistance, allergy, adverse events or unavailability of the drug; use of novel agents may be necessary to adequately treat this MDR infection and overcome these limitations. Case description This small case series describes two patients who underwent treatment with tigecycline for ventilator‐associated pneumonia (VAP) caused by S. maltophilia after admission to a trauma intensive care unit. At the time of admission for the two reported patients, a national drug shortage of intravenous (IV) SMX/TMP prevented its use. Tigecycline was chosen as a novel agent to treat S. maltophilia VAP based on culture and susceptibility data, and it was used successfully. Both patients showed clinical signs of improvement with eventual cure and discharge from the hospital after treatment with tigecycline, and one patient demonstrated confirmed microbiological cure with a negative repeat bronchoscopic bronchoalveolar lavage (BAL). What is new and conclusion To our knowledge, this small case series is the first documentation of utilizing tigecycline to treat S. maltophilia VAP in the United States. Although it likely should not be considered as a first‐line agent, tigecycline proved to be an effective treatment option in the two cases described in the setting of a national drug shortage of the drug of choice.

14 June 2024 in Journal of Surgical Research
Verified
Journal Article
Closed access
JFJulie Farrar
Julie Farrar
JSJoseph Swanson
Joseph Swanson
JHJoanna Q. Hudson
Joanna Q. Hudson
SBSaskya Byerly
Saskya Byerly
DFDina Filiberto
Dina Filiberto
RDRoland N Dickerson
Roland N Dickerson

16 July 2025 in Journal of Critical Care
Verified
Journal Article
Closed access
AEAlyson M. Esteves
Alyson M. Esteves
BBBrittney Bernardoni
Brittney Bernardoni
SBSophia Brown
Sophia Brown
JFJulie Farrar
Julie Farrar
DFDina Filiberto
Dina Filiberto
BMBrian Murray
Brian Murray